1. Additional file 1 of Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment
- Author
-
Valdez-Cruz, Norma A., García-Hernández, Enrique, Espitia, Clara, Cobos-Marín, Laura, Altamirano, Claudia, Bando-Campos, Carlos G., Cofas-Vargas, Luis F., Coronado-Aceves, Enrique W., González-Hernández, Ricardo A., Hernández-Peralta, Pablo, Juárez-López, Daniel, Ortega-Portilla, Paola A., Restrepo-Pineda, Sara, Zelada-Cordero, Patricio, and Trujillo-Roldán, Mauricio A.
- Subjects
body regions ,viruses ,fungi ,skin and connective tissue diseases ,respiratory tract diseases - Abstract
Additional file 1: Table S1. Participation of the immune system in the infection by SARS-CoV-2. Table S2. Summary of outcomes regarding the use of convalescent plasma from COVID-19 patients. Table S3. Binding affinity of monoclonal antibodies that block or neutralize interaction between SARS-CoV-2 and hACE2. Table S4. Clinical evaluation of mAbs against SARS-CoV-2. Table S5. Binding affinity of nanobodies that block or neutralize interaction between SARS-CoV-2 and hACE2. Table S6. Process and product related potential critical quality attributes (pCQAs) to be taken into account for the production of anti-SARS-CoV-2 mAbs to obtain a pure active pharmaceutical ingredient.
- Published
- 2021
- Full Text
- View/download PDF